U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07602582) titled 'A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).' on May 15.
Brief Summary: The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Alzheimer Disease
Dementia
Plaque, Amyloid
Intervention:
DRUG: Donanemab
Administered IV
DRUG: Placebo
Administered IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Published by HT D...